Nvidia Unveils BioNeMo, A GenAI Platform Designed for Drug Discovery and Healthcare Innovations

NVIDIA has recently unveiled — BioNeMo, a generative AI platform designed for drug discovery. It offers a range of tools to simplify and accelerate the training of models using your own data, and it facilitates the scaling of model deployment for drug discovery applications. The platform provides state-of-the-art biomolecular models for tasks such as 3D protein structure prediction, de novo protein and small molecule generation, property predictions, and molecular docking.

NVIDIA says that its latest BioNeMo foundation models can analyze DNA sequences, predict how proteins will change shape in response to a drug molecule, and determine a cell’s function based on its RNA.

BioNeMo offers pretrained models, such as MegaMolBART and MoFlow for chemistry, and ESM-1 and ESM-2 for protein embeddings. BioNeMo also allows researchers to customize and deploy generative and predictive biomolecular AI models at scale.

This generative AI platform also simplifies and speeds up training models using your own data. For example, generative AI can analyze and visualize large amounts of data to identify emerging trends, key players, and potential opportunities. This can help R&D teams and innovation-driven companies gain insights that can inform research priorities and investment strategies.

BioNeMo also features a turnkey solution accessible through a web interface or cloud APIs, allowing users to access pretrained models for interactive inference, visualization, and experimentation. It's designed to provide seamless and scalable AI services, with the flexibility to experiment and build enterprise-grade generative AI workflows.

For those interested in the technical development and deployment of AI models, BioNeMo offers training services optimized for drug discovery, with support for various models, data loaders, training workflows, and validation processes. The platform can be accessed through the NVIDIA Base Command Platform for NVIDIA DGX Cloud.

 

Resources for BioNeMo Framework

Additionally, BioNeMo's ecosystem includes documentation, tutorials, and community support to help users explore its capabilities further.

NVIDIA's BioNeMo platform is at the forefront of a collaboration with Cognizant to enhance drug discovery for pharmaceutical clients. This partnership leverages generative AI to tackle complex challenges in the life sciences industry, aiming to improve productivity and speed up the development of new treatments.

Cognizant brings its AI and industry expertise to the table, utilizing NVIDIA's pretrained, industry-specific generative AI models to provide clients with a suite of model-making services. These services are designed to reduce manual intervention for data analysis and eliminate the need for extensive coding and infrastructure maintenance.

Furthermore, NVIDIA and Microsoft have expanded their collaboration in healthcare innovation, which includes the application of generative AI technology with the NVIDIA BioNeMo platform to address drug discovery challenges. This collaboration seeks to enhance productivity in development processes and hasten the delivery of new treatments to the market.

Cognizant also plans to establish an NVIDIA AI Center of Excellence this year to continue innovating with NVIDIA technologies across various domains, including manufacturing and automotive engineering. This center will focus on leveraging generative AI to bolster productivity, streamline costs, and expedite innovation.

Besides, BioNeMo models will soon be accessible on AWS HealthOmics, a purpose-built service that helps healthcare and life sciences organizations store, query and analyze biological data including DNA and RNA.

NVIDIA says that Cadence and Iambic Therapeutics are among more than 100 companies adopting NVIDIA AI to propel computer-aided drug discovery and generative AI.

Advertisements